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A B S T R A C T   
Tumors of the ear with neuroendocrine features are a very rare group of neoplasms, with neuroendocrine ad-
enoma representing the more frequent entity found; the prevalence of middle ear neuroendocrine tumors is so 
low that it has never been determined exactly. 
Herein we describe the case of a 74 years old woman who presented a pure moderately differentiated middle 
ear neuroendocrine tumor after a long history of adhesive otitis media. Patient abruptly developed otalgia and a 
sense of plugged ear. Otomicroscopy revealed a polypoid mass of the external auditory canal. On histopathologic 
exam a neoplastic proliferation of monomorphous epithelioid cells arranged in small nests and clusters was 
present, being positive to cytokeratins, chromogranin, synaptophysin and CD56, and negative to S100. Ki-67 
proliferation index was 20%. The lesion was diagnosed as a moderately differentiated neuroendocrine tumor 
(NET grade 2). CT and PET scans highlighted the concurrent presence of locoregional lymph nodes involvement 
but also at distance liver metastases. 
The patient underwent chemotherapy and liver repetitions were treated locally. At the time of the writing the 
patient is in good general condition. 
We describe an exceeding rare case of a moderately differentiated neuroendocrine tumor with primitivity in 
the middle ear and concurrent distant metastasis at the time of the diagnosis. 
This case represents a clinical and histological challenge, for the rarity of the lesion and the aspecific symp-
toms of the patient.   
1. Introduction 
Neuroendocrine neoplasms (NENs) of head and neck region repre-
sent a rare group of epithelial lesions [1], with heterogeneous clinical, 
pathological and prognostic features. Moreover, the complexity of this 
district, with different subsites, leads to difficulties in uniforming clas-
sification and management of the majority of these neoplasms. 
The 4th edition of World Health Organisation (WHO) classifies 
neuroendocrine neoplasms into three grades of differentiation - well 
differentiated (carcinoid, neuroendocrine tumors - NET - grade 1), 
moderately differentiated (atypical carcinoid, neuroendocrine tumors - 
NET - grade 2) and poorly differentiated (neuroendocrine carcinomas - 
NEC) neoplasms, with the latter further subclassified into small cell 
carcinoma (SCNEC) and large cell carcinoma (LCNEC) [2]. 
Neuroendocrine neoplasms are discussed in the larynx section as the 
4th WHO edition reports the different neoplasms according to the sub-
site where they are more frequently found. Indeed, in the chapter 
dedicated to middle and inner ear neoplasms only one lesion with 
neuroendocrine features is described, which is middle ear adenoma, as it 
is a site specific tumor. Middle ear adenoma is a benign lesion, with low 
grade potential of recurrences and local metastasis, composed of a dual 
cell population of epithelial exocrine cells and neuroendocrine elements 
[2]. Nomenclature is still controversial, as this lesion is often called 
“neuroendocrine adenoma”, “adenomatous tumor”, “middle ear ade-
noma with neuroendocrine differentiation” and “carcinoid of the middle 
ear”. The latter terminology is confusing, as “carcinoid” refers to a 
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malignant, well differentiated pure neuroendocrine neoplasm. Although 
some authors [3] suggest that neuroendocrine adenoma and carcinoid 
must be considered as the same entity, others [4] prompt that they are 
two different neoplasms. The latter theory is supported by the risk of 
distant metastatic disease occasionally found in literature in cases of 
middle ear carcinoid (NET grade 1) which is never reported in neuro-
endocrine adenoma [5,6]. Moreover, it is possible that primary middle 
ear tumors with neuroendocrine features which develop distant metas-
tasis could be more aggressive lesions than neuroendocrine adenomas 
and could behave as atypical carcinoids, being classified as carcinoids 
for the localization of the primary tumor. 
Herein we present an exceedingly rare case of a late onset pure 
primitive middle ear moderately differentiated NET of the middle ear 
occurring over a long lasting chronic fibro-adhesive middle ear otitis, 
with local lymph nodes and, overall, distant metastasis at the time of the 
diagnosis. 
2. Case report 
M.A., a 74 years old woman, had been followed for 30 years at the 
Audiology Unit of Careggi University Hospital in Florence for recurrent 
otitis since her childhood. At the age of 38 the patient started being 
regularly studied for a left moderate conductive hearing loss not wors-
ening over time except for the presbycusis component. Since the first 
evaluation, the otomicroscopic examination showed a very mild 
retraction of the whole right eardrum and a subtotal atelectasis of the 
left tympanic cavity as a consequence of a chronic fibro-adhesive otitis. 
ENT examination was otherwise negative. The patient remained stable 
until she was 68, when she abruptly started complaining of pain and a 
sense of plugging in the left ear, without fluid leaking. An otomicroscopy 
was performed, revealing the presence of a soft, not bleeding, hyalinoid, 
polypous-like lesion located in the postero-superior area of the external 
auditory canal. Pure tone audiometry showed a left mixed hearing loss, 
with the air conduction hearing threshold slightly worsened compared 
to the one detected in the previous exams and with a stable bone con-
duction hearing threshold. Tympanogram showed a C-type pattern in 
the right ear and a B-type pattern in the left ear. The patient started local 
and general antibiotic and corticosteroid therapy without clinical 
improvement thus a cranial CT scan was performed, showing the pres-
ence of an isodense material occupying the epitympanum and the 
mastoid, encasing the ossicles, without clear bone erosion and extending 
into the outer ear canal, occupying it almost completely (Fig. 1). 
In the clinical suspect of a chronic hyperplastic otitis media, a canal 
wall-up mastoidectomy was programmed. At surgery, the mastoid and 
the tympanic cavity were diffusely occupied by a soft, grey-pink 
redundant tissue that was not surely ascribable to a hyperplastic flo-
gosis. This material actually encased the ossicles, with partial resorption 
of the stapes crura. After a complete toilette of the middle ear cavities, 
an ossiculoplasty was also performed in order to preserve the hearing 
function. The material was sent for histological examination. 
Microscopic exam showed middle ear epithelium composed of a 
normal single layer of ciliated cells and a deep neoplastic proliferation of 
monomorphous epithelioid cells arranged in small nests and clusters. 
Neoplastic elements showed cuboidal shapes and mild pleomorphism, 
with uniform round to oval nuclei and finely dispersed chromatin. 
Mitotic figures were rare and necrosis was absent. Immunohistochem-
istry showed uniform positive stain to pan-cytokeratin cocktail (clone 
AE1/AE3/PCK2 and CAM5.2, Ventana, Roche) chromogranin (clone 
LK2H10, Ventana, Roche) synaptophysin (clone MRQ40, Ventana, 
Roche) and CD56 (MRQ-42, Ventana Roche), and negative stain for 
S100 (clone 4C4.19, Ventana Roche). Ki-67 (clone 30-9, Ventana Roche) 
was 20%. The tumor was diagnosed as a moderately differentiated 
neuroendocrine carcinoma. Immunohistochemistry for TTF1(clone 
SP141, Ventana Roche), CDX2 (clone EPR2764Y, Ventana, Roche) and 
CK20 (SP33, Ventana, Roche) were performed, with negative results, in 
order to exclude lung and gastrointestinal primitivity (Fig. 2). 
For staging purposes, an enhanced total body CT scan and a total 
body FDG PET were performed; these exams showed multiple later-
ocervical and abdominal metastatic lymph nodes as well as several liver 
localizations. Moreover, a 68Ga-DOTANOC PET showed a high, diffuse 
expression of somatostatin receptors in all the lesions evidenced (Figs. 3 
and 4). 
After this diagnosis, the patient started chemotherapy with Temodal 
and Capecitabine. The CT scan, performed after 4 cycles of chemo-
therapy, revealed a stable disease. The patient therefore started main-
tenance therapy with Everolimus and Somatostatin analogue in a 
clinical trial that continued until December 2017. A liver biopsy 
confirmed the same histological and immunohistochemical features of 
the primary middle ear tumor, with Ki-67 = 15% that corroborated the 
conviction of the metastatic nature of the disease. Liver metastases were 
treated with a transarterial chemoembolization with Doxorubicin. 
Regular follow up exams were conducted over time and, one year 
after the surgical removal of the primary tumor, two new lymph nodes 
localizations were found, appearing hard and fixed on the deep soft 
tissues, being one in the preauricular region and the other behind the 
mandibular angle. 
In a 5-year follow-up period, the left outer ear canal was free of 
disease and the appearance of the tympanic membrane and middle ear 
cavity remained of the atelectasis type. Audiometric and impedance 
findings did not change overtime. Cranial, petrous bone and maxillo- 
facial direct and enhanced CT scans, performed during follow up, evi-
denced stable lesions as concerned to middle ear pathology and 
locoregional repetitions, the latter sometimes increasing in number and 
localization sometimes reducing, especially with regard to the intra-
parotid nodularities. 
The patient remained stable until 2018, when abdominal CT scan 
demonstrated the progression of the disease in the liver and in the 
abdominal lymph nodes, requiring a new line of chemotherapy and 
radiometabolic treatment. 
In January 2020 a CT scan revealed a further progression of the liver 
metastasis and the patient was submitted to a new hepatic needle biopsy 
which confirmed the metastatic nature of the disease. The patient thus 
Fig. 1. On the left side, axial CT scan shows a total opacification of mastoid 
cells and the presence of isodense tissue in the middle ear cavity without signs 
of ossicular chain erosion. Labyrinthine structures do not show any 
involvement. 
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started a new line of chemotherapy with Oxaliplatin and 5-Fluorouracil, 
that is still in progress. 
At the last follow up in November 2020, six years after the diagnosis, 
the otological, clinical and radiological examinations did not highlight 
any disease recurrence or progression and the patient was in good 
general conditions. 
3. Discussion 
We report a rare case of moderately differentiated neuroendocrine 
tumor with primitivity in the middle ear and simultaneous regional but, 
overall, distant metastasis. 
This case is particularly challenging both for clinical and for patho-
logical features. 
Clinically, acute ear pain and a sense of plugged ear abruptly com-
plained by the patient were not ascribable to any specific inflammatory 
or neoplastic condition. Moreover, the otoscopic exam only revealed a 
polypoid mass protruding in the external auditory canal, apparently 
involving the middle ear structures. All these elements suggested a 
reactivation of the underlying chronic phlogistic process, and local and 
Fig. 2. A, neoplastic cells with nested and solid pattern of growth; monotonous cell elements with high nuclear/cytoplasmic ratio; B–C, cells show positivity to 
chromogranin and synaptophysin markers, confirming neuroendocrine nature of the lesion; D, Ki-67 is 20%. 
Fig. 3. Head and neck PET scan highlights left laterocervical and preauricular 
lymph nodes. 
Fig. 4. Abdominal PET scan shows early liver involvement.  
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systemic pharmacological therapy were considered the first treatment 
for the patient. 
Moreover, imaging did not help in clarifying the specific nature of 
the lesion, as petrous bone CT scan performed after the lack of clinical 
improvement indicated the presence of an unspecified pathological tis-
sue involving the epitympanum, the antrum and the mastoid, encasing 
the ossicles without signs of clear erosion. 
The diagnosis of moderately differentiated neuroendocrine tumor 
was made after microscopic and immunohistochemical histological ex-
amination on the surgical sampling. 
Compared to the similar cases described in literature, classified both 
as middle ear “adenoma” and “carcinoid”, some clinical differences 
emerge: the age of the subjects described in literature is generally lower, 
at the time of the diagnosis, than that of our patient, as they were all 
younger than 50 years old except in one case [7]; the starting symptoms 
complained by literature framed patients were mainly hearing loss, 
tinnitus and otorrhea [8–16], just three of them complaining only ear 
pain, accompanied in two cases with a sense of plugged ear [17–19]. 
Middle ear adenomas and carcinoids are usually treated only with sur-
gery (tympanomastoidectomy) [8–20]; chemotherapy and radiotherapy 
have been sometimes added in some difficult cases reported by litera-
ture, essentially because of the relapsing behaviour of the disease [11, 
12]. Conversely, as soon as surgical therapy was performed, our patient 
started to receive the suitable chemotherapeutic treatment for neuro-
endocrine tumors. 
Even though various non neoplastic and benign conditions can 
resemble it [13,18,21] macroscopically the lesion that we found was 
immediately suspicious for an uncommon neoplastic process. Indeed, 
paraganglioma presents like a reddish pulsatile vascular mass that can 
protrude through the tympanic membrane into the external auditory 
canal, while cholesteatoma is usually associated to an epithelial matrix: 
such features were not present in our case. 
Also the clinical behaviour of the lesion suggested a malignant 
neoplasm, as neck lymph nodes and liver metastases were found during 
staging exams. Compared to other middle ear tumors with neuroendo-
crine features described in literature, our case showed a more aggressive 
behaviour; actually our patient developed liver metastasis almost 
simultaneously with the primitive lesion, while the sporadic metastatic 
tumors reported by others manifested repetitions only very late [6,7,12, 
22]. 
On histopathologic examination, the lesion showed morphological 
and immunohistochemical features coherent with a pure neuroendo-
crine neoplasm, with a moderate grade of differentiation both in the 
middle ear and in the liver metastasis. The final diagnosis was “middle 
ear neuroendocrine tumor, grade 2”, according to the 4th edition of the 
WHO. 
The spectrum of differential diagnosis is very wide and comprise 
lesions of different nature. 
Among benign lesions, the main differential diagnosis is with middle 
ear neuroendocrine adenoma, which is a site specific lesion, with 
neuroendocrine differentiation. Nevertheless, our lesion lacked the 
typical amphicrine cell growth seen in neuroendocrine adenomas, that 
show both endocrine cells containing neurosecretory granules and 
exocrine elements often containing mucous granules arranged in nests 
or glandular structures [23]. 
Jugulotympanic paraganglioma, which is the most frequent middle 
ear tumor, has to be considered in the differential diagnosis. In our case 
no vascular-rich stroma was seen and cells were positive to cytokeratins, 
thus paraganglioma was excluded [2]. Another nerve sheet tumor that 
can mimic the case herein described is vestibular schwannoma, espe-
cially in small biopsies and fragmented specimens [24]. However, 
schwannoma is composed of spindle cells arranged in typical cellular 
(Antoni A) areas and hypocellular (Antoni B) areas and Verocay bodies, 
and shows positivity to S100 with negative epithelial markers. Menin-
gioma can involve the middle ear, but it has peculiar histological fea-
tures that are not seen in neuroendocrine tumors, as whorled patterns of 
growth, intranuclear inclusions and psammomatous bodies [25]. 
A number of malignant lesions of the middle ear can resemble NET, 
as adenocarcinoma, malignant glomus tumor and rhabdomyosarcoma, 
even if all of them show histological peculiar features that can help in 
the differential diagnosis. Indeed, adenocarcinoma shows more pleo-
morphism, necrosis and a high mitotic activity, while malignant glomus 
tumor has a typical vascular and capillary network surrounding the 
lesion [26,27]. Moreover, both lesions lack the expression of neuroen-
docrine markers. Rhabdomyosarcoma, especially the alveolar variant, 
can be similar to NET for the presence of plasmacytoid elements and it 
can be aberrantly positive for cytokeratins and neuroendocrine markers. 
However, the peculiar expression of desmin and myogenin helps to 
recognize this entity [28]. 
For the involvement of the external auditory canal and the neuro-
endocrine features, Merkel cell carcinoma has also to be excluded. While 
histological features are similar, as Merkel cell carcinoma is considered a 
primary cutaneous neuroendocrine tumor, CK20 is a very useful 
immunohistochemical marker, that is positive in this lesion, with a 
classical dot-like paranuclear stain [29]. In our case CK20 was per-
formed with a negative result. 
Hepatic lesions of our patient displayed the same histological and 
immunohistochemical features of the middle ear NET, so they were 
diagnosed as metastatic. A primitive NET of the liver is a very rare 
lesion, usually found in young adults, while the liver is one of the most 
common sites of metastasis of other district NET [12,22]. 
4. Conclusions 
Considering all the above, we think it is very important to carefully 
follow over time chronic phlogistic pathologies of the middle ear, not 
only those of paediatric or of the young age but even those who present 
in advanced age subjects, even if long standing, being aware that, 
although in extremely rare cases, it is possible that they will turn into 
neoplastic forms of a neuroendocrine nature, capable of metastasizing at 
a distance, also very soon. 
It must always be taken in account that symptoms of a newly 
developed NEN lesion into the middle ear couldn’t differ too much from 
those of a sudden riacutization of a chronic otitis and that the objective 
clinical picture could continue to give evidence of a phlogistic patho-
logical process despite its malignant nature. 
Therefore, regardless of the patient’s age, a new acute lesion into the 
external and/or middle ear, resistant to general and local therapy, 
although with the appearance of a lesion of an inflammatory nature, 
should induce to consider, among the other more frequent diagnostic 
hypotheses, also the possibility of a pure NET of the middle ear with a 
minor or major malignant potential. 
Histologically, the correlation with clinical information and imaging, 
with the help of immunohistochemistry, can differentiate primary 
middle ear neuroendocrine lesions from metastases and from neuroen-
docrine neoplasms of lung or gastrointestinal tract. Moreover, all 
neuroendocrine tumors have to be carefully classified according to the 
4th WHO classification, in order to have a uniform terminology and 
avoid confusion. 
Early diagnosis of these extremely rare forms would allow the best 
therapeutic approach, surgical, medical or both, in order to limit their 
evolution and repetitions. 
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